SCHEMBL2913341

SCHEMBL2913341

O=C(O)c1c[nH]c2sccc2c1=O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSNK2A1 P68400 4/20 0.47
CSNK2A2 P19784 3/20 0.47
CSNK2B P67870 3/20 0.47
KDM4E B2RXH2 3/20 0.46
CYP1A2 P05177 2/20 0.46
HSD17B10 Q99714 2/20 0.46
PIM3 Q86V86 1/20 0.45
CLK4 Q9HAZ1 1/20 0.45
HPGD P15428 4/20 0.43
ALDH1A1 P00352 3/20 0.43
MEN1 O00255 1/20 0.43
ALOX12 P18054 1/20 0.43
KMT2A Q03164 1/20 0.43
DNA2 P51530 1/20 0.42
CASP6 P55212 1/20 0.42
CTDSP1 Q9GZU7 1/20 0.42
TET2 Q6N021 1/20 0.40
TET1 Q8NFU7 1/20 0.40
HTT P42858 1/20 0.39
TNKS O95271 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8159994 0.85 HSD17B10 (0.49) CSNK2A1CSNK2A2CSNK2BKDM4EHSD17B10
SCHEMBL6332699 0.85 ALDH1A1 (0.42) CSNK2A1CSNK2A2CSNK2BKDM4EHSD17B10
SCHEMBL13229579 0.81 ALDH1A1 (0.41) CYP1A2HSD17B10HPGDALDH1A1MEN1
SCHEMBL8160644 0.80 ALDH1A1 (0.37) CSNK2A1PIM3CLK4ALDH1A1MEN1
SCHEMBL13229585 0.79 CFTR (0.63) KDM4EHSD17B10HPGDALDH1A1MEN1
SCHEMBL7504551 0.77 CLEC4M (0.58) KDM4ECYP1A2HSD17B10HPGDALDH1A1
SCHEMBL7479578 0.76 ADORA2A (0.61) KDM4ESMN1; SMN2
SCHEMBL7007466 0.76 HTR2A (0.47) KDM4EALDH1A1MEN1KMT2ACASP6
SCHEMBL15562849 0.75 ALDH1A1 (0.49) HSD17B10PIM3ALDH1A1MEN1KMT2A
SCHEMBL29196577 0.74 KDM4E (0.53) CSNK2A1CSNK2A2CSNK2BKDM4ECYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8193215-B2 Thieno[2 3-b]pyridines as potassium channel inhibitors XENTION LIMITED (GB) 2012-06-05 US disclosed
EP-1879899-B1 THIENOPYRIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS XENTION LTD (GB) 2010-08-04 EP disclosed
US-20100041695-A1 Thieno[2,3-b]pyridines as Potassium Channel Inhibitors XENTION LIMITED (GB) 2010-02-18 US disclosed
US-7576212-B2 Thieno[2,3-B] pyridines as potassium channel inhibitors XENTION LIMITED (GB) 2009-08-18 US disclosed
EP-1879899-A1 THIENOPYRIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS Xention Discovery Limited (GB) 2008-01-23 EP disclosed
US-20060183768-A1 Compounds XENTION DISCOVERY LTD. (GB) 2006-08-17 US disclosed
WO-2006061642-A1 COMPOUNDS XENTION DISCOVERY LIMITED (GB) 2006-06-15 WO disclosed
CN-1092197-C Bicyclic thiophene derivatives and use as gonadotropin releasing hormone antagonists TAKEDA CHEMICAL INDUSTRIES LTD (JP) 2002-10-09 CN disclosed
EP-0781774-B1 Prolactin production inhibitory agents TAKEDA CHEMICAL INDUSTRIES LTD (JP) 2002-07-31 EP disclosed
US-6015789-A LUTEINIZING HORMONE RELEASING HORMONE AGONIST AND A LUTEINIZING HORMONE RELEASING HORMONE ANTAGONIST IN COMBINATION, TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2000-01-18 US disclosed
US-5977132-A GALACTORRHEA, HYPERPROLACTINEMIC OVULATION, PROLACTINOMA AND BRAIN TUMORS TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1999-11-02 US disclosed
EP-0906115-A1 COMBINED USE OF GnRH AGONIST AND ANTAGONIST Takeda Chemical Industries, Ltd. (JP) 1999-04-07 EP disclosed
WO-1997040846-A1 COMBINED USE OF GnRH AGONIST AND ANTAGONIST TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1997-11-06 WO disclosed
EP-0781774-A2 Prolactin production inhibitory agents TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1997-07-02 EP disclosed
CN-1146206-A Bicyclic thiophene derivatives and use as gonadotropin releasing hormone antagonists TAKEDA CHEMICAL INDUSTRIES LTD (JP) 1997-03-26 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100041695-A1 Thieno[2,3-b]pyridines as Potassium Channel Inhibitors SCN8A, SCN1B, SCN2B CSNK2A1 844/4885CSNK2A2 636/4885CSNK2B 490/4885
US-20060183768-A1 Compounds SCN7A, CBR3, SCN8A CSNK2A1 1136/4885CSNK2A2 892/4885CSNK2B 876/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.